TLR7 regulates dendritic cell-dependent B-cell responses through BlyS in immune thrombocytopenic purpura

European Journal of Haematology

Volumn 86, Issue 1, 2011, Pages 67-74

  Yu, Huiming ^a,b   Liu, Yunfang ^b   Han, Junqing ^b   Yang, Zhe ^b   Sheng, Wei ^b   Dai, Honghai ^b   Wang, Yingjie ^a   Xia, Tingyi ^a   Hou, Ming ^b  

^a Cancer Center   (Belgium)

^b SHANDONG UNIVERSITY   (China)

Author keywords

B cells; B lymphocyte stimulator; Dendritic cells; Immune thrombocytopenic purpura; Toll like receptor 7

Indexed keywords

ANTIBODY; B CELL ACTIVATING FACTOR; CD14 ANTIGEN; CD19 ANTIGEN; GLYCOPROTEIN; MESSENGER RNA; TOLL LIKE RECEPTOR 7;

ADOLESCENT; ADULT; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; CELL SURVIVAL; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MALE; MONOCYTE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIGEN-PRESENTING CELLS; AUTOANTIBODIES; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; CASE-CONTROL STUDIES; CELLS, CULTURED; DENDRITIC CELLS; GLYCOPROTEINS; MONOCYTES; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RNA, MESSENGER; TOLL-LIKE RECEPTOR 7;

EID: 78650103795     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2010.01534.x     Document Type: Article

References (42)

1. Berchtold P, Wenger M. Autoantibodies against platelet glycoproteins in autoimmune thrombocytopenic purpura: their clinical significance and response to treatment. Blood 1993;81:1246-50.
2. Kuwana M, Kaburaki J, Ikeda Y. Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura: role in production of anti-platelet autoantibody. J Clin Invest 1998;102:1393-402.
3. Zhu XJ, Shi Y, Sun JZ, et al. High-dose dexamethasone inhibits BAFF expression in patients with immune thrombocytopenia. J Clin Immunol 2009;29:603-10.
4. Fu L, Lin-Lee YC, Pham LV, et al. BAFF-R promotes cell proliferation and survival through interaction with IKKbeta and NF-kappaB/c-Rel in the nucleus of normal and neoplastic B-lymphoid cells. Blood 2009;113:4627-36.
5. Mackay F, Woodcock SA, Lawton P, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999;190:1697-710.
6. Reyes SLI, Leon BF, Rozas VMF, Gonzalez JP, Naves PR. BAFF: a regulatory cytokine of B lymphocytes involved in autoimmunity and lymphoid cancer. Rev Med Chil 2006;134:1175-84.
7. Roberto S, Nichola C, Giovanni DP, et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell depleting therapy with rituximab. Blood 2008;112:1147-50.
8. Mariette X, Roux S, Zhang J, et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis 2003;62:168-71.
9. Emmerich F, Bal G, Barakat A, et al. High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura. Br J Haematol 2007;136:309-14.
10. Zhu XJ, Shi Y, Peng J, et al. The effects of BAFF and BAFF-R-Fc fusion protein in immune thrombocytopenia. Blood 2009;114:5362-7.
11. Yu HM, Liu YF, Hou M. BAFF - an essential survival factor for B cells: links to genesis of ITP and may be of therapeutic target. Med Hypotheses 2008;70:40-2.
12. Zhang XL, Peng J, Sun JZ, et al. Modulation of immune response with cytotoxic T-lymphocyte-associated antigen 4 immunoglobulin- induced anergic T cells in chronic idiopathic thrombocytopenic purpura. J Thromb Haemost 2007;6:158-65.
13. Zhou Z, Li X, Li J, Su C, Zhuang L, Luo S, Zhang L. Direct B-cell Stimulation by Peripheral Blood Monocyte-derived Dendritic Cells in Idiopathic Thrombocytopenic Purpura Patients. J Clin Immunol 2010;Jul 14. [Epub ahead of print].
14. Douagi I, Gujer C, Sundling C, et al. Human B cell responses to TLR ligands are differentially modulated by myeloid and plasmacytoid dendritic cells. J Immunol 2009;182:1991-2001.
15. Wan SG, Zhou ZH, Duan BY, Morel L. Direct B cell stimulation by dendritic cells in a mouse model of lupus. Arthritis Rheum 2008;58:1741-50.
16. Litinskiy MB, Nardelli B, Hilbert DM, et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002;3:822-9.
17. Schneider P, MacKay F, Steiner V, et al. Tschopp J. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999;189:1747-56.
18. Balazs M, Martin F, Zhou T, Kearney J. Blood dendritic cells interact with splenic marginal zone B cells to initiate T independent immune responses. Immunity 2002;17:341-52.
19. Gross JA, Johnston J, Mudri S, et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000;404:995-9.
20. Joanna RG, Carrie AF, Stacey NW, et al. BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J Exp Med 2007;204:1959-71.
21. Donna LT, Alvina DC, Kareem LG, Imelda B, Lowen YL, Cassidy K. IRF9 and STAT1 are required for IgG autoantibody production and B cell expression of TLR7 in mice. J Clini Invest 2008;118:1417-26.
22. Tomai MA, Imbertson LM, Stanczak TL, Tygrett LT, Waldschmidt TJ. The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes. Cell Immunol 2000;203:55-65.
23. Bishop GA, Hsing Y, Hostager BS, Jalukar SV, Ramirez LM, Tomai MA. Molecular mechanisms of B lymphocyte activation by the immune response modifier R-848. J Immunol 2000;165:5552-7.
24. Bishop GA, Ramirez LM, Baccam M, Busch LK, Pederson LK, Tomai MA. The immune response modifier resiquimod mimics CD40-induced B cell activation. Cell Immunol 2001;208:9-17.
25. Shen E, Lu L, Wu C. TLR7/8 Ligand, R-848, Inhibits IgE Synthesis by Acting Directly on B Lymphocytes. Scand J Immunol 2008;67:560-8.
26. Glaum MC, Narula S, Song D, Zheng Y, Anderson AL, Pletcher CH. Toll-like receptor 7-induced naive human B-cell differentiation and immunoglobulin. J Allergy Clin Immunol 2009;123:224-30.
27. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis ESC. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004;303: 1529-31.
28. Sood R, Wong W, Gotlib J, Jeng M, Zehnder JL. Gene expression profile of idiopathic thrombocytopenic purpura (ITP). Pediatr Blood Cancer 2006;47(5 Suppl):675-7.
29. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113:2386-93.
30. Pirhonen J, Sareneva T, Kurimoto M, Julkunen I, Matikainen S. Virus infection activates IL-1β and IL-18 production in human macrophages by a caspase-1-dependent pathway. J Immunol 1999;162:7322-9.
31. Michael W, Graham W, Demple HL. Relative expression software tool (REST©) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 2002;30:1-10.
32. Chu VT, Enghard P, Schürer S, Steinhauser G, Rudolph B, Riemekasten G. Systemic activation of the immune system induces aberrant BAFF and APRIL expression in B cells in patients with systemic lupus erythematosus. Arthritis Rheum 2009;60:2083-93.
33. Nakajima K, Itoh K, Nagatani K, Okawa-Takatsuji M, Fujii T, Kuroki H. Expression of BAFF and BAFF-R in the synovial tissue of patients with rheumatoid arthritis. Scand J Rheumatol 2007;36:365-72.
34. MacLennan I, Vinuesa C. Dendritic cells, BAFF, and APRIL: innate players in adaptive antibody responses. Immunity 2002;17:235-8.
35. Aslam R, Speck ER, Kim M, et al. Platelet Toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor-alpha production in vivo. Blood 2006;107:637-41.
36. Clark SR, Ma AC, Tavener SA, et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med 2007;13:463-9.
37. Leadbetter EA, Rifkin IR, Hohlbaum AM, et al. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002;416:603-7.
38. Franck JB, Thea M, Jean HC, et al. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur J Immunol 2007;37:3582-6.
39. Ludewig B, Junt T, Hengartner H, Zinkernagel RM. Dendritic cells in autoimmune disease. Curr Opin Immunol 2001;13:657-62.
40. Mehling A, Beissert S. Dendritic cells under investigation in autoimmune disease. Crit Rev Biochem Mol Biol 2003;38:1-21.
41. Bayry J, Thirion M, Delignat S, et al. Dendritic cells and autoimmunity. Autoimmun Rev 2004;3:183-7.
42. Yaiza DD, George TM, Richard JB, Alessandra F. B cell-dendritic cell cooperation is required for via TACI-BLyS signaling CD8+ T cell priming in vivo. Blood 2006;107:594-601.